Key result
Elevated resting heart rate is a key indicator of adverse outcomes in heart failure, and heart rate reduction with agents like ivabradine improves cardiovascular outcomes.
Why the study?
Does heart rate reduction improve cardiovascular outcomes in patients with heart failure?
Does heart rate reduction improve cardiovascular outcomes in patients with heart failure?
Elevated resting heart rate is a key indicator of adverse outcomes in heart failure and represents a major treatment target.
Answers are grounded in this paper and cite their sources.
Warrants monitoring heart rate in HF; leaves open optimal agents and populations pending prospective trials.
PURPOSE OF REVIEW: The clinical data about the impact of heart rate reduction in heart failure therapy will be reviewed. RECENT FINDINGS: Clinical and experimental studies showed an association between elevated resting heart rate and mortality risk in heart failure patients. This review summarizes that heart rate level at rest and its extent of reduction is a sensitive indicator for outcome in heart failure. In addition to the nonspecific heart rate reducing drugs like β-blockers, cardiac glycosides and Ca(2+) antagonists, ivabradine is a highly selective heart rate reducing agent without modifying ventricular contractility and atrioventricular conduction in humans and animals, and has recently been shown to improve cardiovascular outcomes in patients with systolic heart failure by lowering the heart rate only. The present and future role of heart rate reduction in the spectrum of heart failure disease and therapy will be outlined and evaluated. SUMMARY: Elevated heart rate at rest represents a key indicator of adverse outcome in heart failure and implies a major treatment target in these patients.
No takes yet. Share an insight, caveat, or question.
Reil et al. (2013) conducted a review in Heart failure. Heart rate reduction (e.g., ivabradine, β-blockers) was evaluated on Cardiovascular outcomes and mortality risk. Elevated resting heart rate is a key indicator of adverse outcomes in heart failure, and heart rate reduction with agents like ivabradine improves cardiovascular outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: